TY - JOUR
T1 - A Meta-Analysis of Mesenchymal Stem Cells in Animal Models of Parkinson's Disease
AU - Riecke, Jenny
AU - Johns, Katherine M.
AU - Cai, Chunyan
AU - Vahidy, Farhaan Shaheer
AU - Parsha, Kaushik
AU - Furr-Stimming, Erin
AU - Schiess, Mya
AU - Savitz, Sean I.
N1 - Publisher Copyright:
© Copyright 2015, Mary Ann Liebert, Inc. 2015.
Copyright:
Copyright 2021 Elsevier B.V., All rights reserved.
PY - 2015/9/15
Y1 - 2015/9/15
N2 - Multiple studies have been performed to evaluate the effects of mesenchymal stem cells (MSCs) in animal models of Parkinson's disease (PD). We performed a meta-analysis to estimate the treatment effect of unmodified MSCs on behavioral outcomes in preclinical studies of PD. We performed a systematic literature search to identify studies that used behavioral testing to evaluate the treatment effect of unmodified MSCs in PD models. Meta-analysis was used to determine pooled effect size for rotational behavior and limb function, and meta-regression was performed to explore sources of heterogeneity. Twenty-five studies, including three delivery routes, a wide range of doses, and multiple PD models, were examined. Significant improvement was seen in the pooled standardized mean difference (SMD) for both rotational behavior [SMD: 1.24, 95% confidence interval (95% CI): 0.84, 1.64] and limb function (SMD: 0.84, 95% CI: 0.01, 1.66). Using meta-regression, intravenous administration and higher dose had a larger effect on limb function. Treatment with MSCs improves behavioral outcomes in PD models. Our analyses suggest that MSCs could be considered for early-stage clinical trials in the treatment of PD.
AB - Multiple studies have been performed to evaluate the effects of mesenchymal stem cells (MSCs) in animal models of Parkinson's disease (PD). We performed a meta-analysis to estimate the treatment effect of unmodified MSCs on behavioral outcomes in preclinical studies of PD. We performed a systematic literature search to identify studies that used behavioral testing to evaluate the treatment effect of unmodified MSCs in PD models. Meta-analysis was used to determine pooled effect size for rotational behavior and limb function, and meta-regression was performed to explore sources of heterogeneity. Twenty-five studies, including three delivery routes, a wide range of doses, and multiple PD models, were examined. Significant improvement was seen in the pooled standardized mean difference (SMD) for both rotational behavior [SMD: 1.24, 95% confidence interval (95% CI): 0.84, 1.64] and limb function (SMD: 0.84, 95% CI: 0.01, 1.66). Using meta-regression, intravenous administration and higher dose had a larger effect on limb function. Treatment with MSCs improves behavioral outcomes in PD models. Our analyses suggest that MSCs could be considered for early-stage clinical trials in the treatment of PD.
UR - http://www.scopus.com/inward/record.url?scp=84940951703&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84940951703&partnerID=8YFLogxK
U2 - 10.1089/scd.2015.0127
DO - 10.1089/scd.2015.0127
M3 - Review article
C2 - 26134374
AN - SCOPUS:84940951703
SN - 1547-3287
VL - 24
SP - 2082
EP - 2090
JO - Stem Cells and Development
JF - Stem Cells and Development
IS - 18
ER -